With the emergence of Dysport, the new competitor of Botox in the United States, the makers of Botox have been stepping things up with a media campaign offering Botox ‘rebates’ to customer who purchased Botox in certain months in 2009. They have also been offering all-expenses-paid trips to doctors and nurses for a company-sponsored medical conference that educates professionals about the wrinkle-fighting drug.
In a recent story in The Daily Telegraph, Allergan spent approximately $1 million educating – and entertaining – doctors and nurses who may use Botox in their practice, putting them up in five-star hotels and providing meals at premium restaurants in the area over the length of the conference.
In Australia, Botox is the most requested treatment in 91 percent of clinics, and Internet searches on Google for Botox treatments in Australia have been up about 200 percent over the past year. In the United States, the American Society of Plastic Surgeons reports that Botox is still the most sought-after minimally invasive procedure. Dysport, the new Botox rival, has yet to make its mark with multi-million dollar sales that Allergan has reported over the years. Allergan reported total product net sales at $1,118.7 million on June 30, 2009, and has also presented to the FDA results from its two Phase III studies on the use of Botox for treating headaches and migraines this summer.
For the full year of 2009, Allergan estimates that total product net sales will be $4,200 million and $4,300 million. This includes sales of Botox (expected to be $1,200 million to $1,220 million), and Latisse (expected to reach $60 million by the end of 2009). (Source: Reuters.com)
Still, Allergan is willing to spend the money towards training and education of its doctors and nurses, and will be rolling out various educational programs for medical practitioners over the next few years.